425 related articles for article (PubMed ID: 30355736)
21. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
22. Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation.
Nieva J; Shafton A; Altobell LJ; Tripuraneni S; Rogel JK; Wentworth AD; Lerner RA; Wentworth P
Biochemistry; 2008 Jul; 47(29):7695-705. PubMed ID: 18578541
[TBL] [Abstract][Full Text] [Related]
23. Methods to study the structure of misfolded protein states in systemic amyloidosis.
Fändrich M; Schmidt M
Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
[TBL] [Abstract][Full Text] [Related]
24. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
[TBL] [Abstract][Full Text] [Related]
25. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
Martin DJ; Ramirez-Alvarado M
Amyloid; 2010 Sep; 17(3-4):129-36. PubMed ID: 21077798
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains.
Rottenaicher GJ; Weber B; Rührnößl F; Kazman P; Absmeier RM; Hitzenberger M; Zacharias M; Buchner J
J Biol Chem; 2021; 296():100334. PubMed ID: 33508322
[TBL] [Abstract][Full Text] [Related]
27. Solid-state NMR chemical shift assignments for AL-09 V
Piehl DW; Blancas-Mejía LM; Ramirez-Alvarado M; Rienstra CM
Biomol NMR Assign; 2017 Apr; 11(1):45-50. PubMed ID: 27771830
[TBL] [Abstract][Full Text] [Related]
28. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril.
Pradhan T; Annamalai K; Sarkar R; Hegenbart U; Schönland S; Fändrich M; Reif B
Biomol NMR Assign; 2021 Apr; 15(1):9-16. PubMed ID: 32946005
[TBL] [Abstract][Full Text] [Related]
29. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
30. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
31. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy.
Ionescu-Zanetti C; Khurana R; Gillespie JR; Petrick JS; Trabachino LC; Minert LJ; Carter SA; Fink AL
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13175-9. PubMed ID: 10557293
[TBL] [Abstract][Full Text] [Related]
32. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
33. Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.
Blancas-Mejía LM; Horn TJ; Marin-Argany M; Auton M; Tischer A; Ramirez-Alvarado M
Biophys Chem; 2015 Dec; 207():13-20. PubMed ID: 26263488
[TBL] [Abstract][Full Text] [Related]
34. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
35. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
36. The Antibody Light-Chain Linker Regulates Domain Orientation and Amyloidogenicity.
Weber B; Hora M; Kazman P; Göbl C; Camilloni C; Reif B; Buchner J
J Mol Biol; 2018 Dec; 430(24):4925-4940. PubMed ID: 30414962
[TBL] [Abstract][Full Text] [Related]
37. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
38. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
39. Atomic structures of amyloid cross-beta spines reveal varied steric zippers.
Sawaya MR; Sambashivan S; Nelson R; Ivanova MI; Sievers SA; Apostol MI; Thompson MJ; Balbirnie M; Wiltzius JJ; McFarlane HT; Madsen AØ; Riekel C; Eisenberg D
Nature; 2007 May; 447(7143):453-7. PubMed ID: 17468747
[TBL] [Abstract][Full Text] [Related]
40. A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding.
Khurana R; Souillac PO; Coats AC; Minert L; Ionescu-Zanetti C; Carter SA; Solomon A; Fink AL
Amyloid; 2003 Jun; 10(2):97-109. PubMed ID: 12964417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
